Immutep
Germany - BerlinBiotechnology
Focus: Immutep is a Berlin-based biotechnology company focused on cell therapies and antibodies, operating at pre-commercial stage with a pipeline concentrated in oncology immunotherapy.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Open Jobs
3+3 this month
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Should You Work at Immutep?
AI assessmentImmutep offers early-stage biotech immersion in immunotherapy but represents higher execution and financial risk due to limited hiring, opaque financials, and early-stage pipeline maturity.
Why Work Here
- Early-stage oncology immunotherapy platform with multiple Phase 2/3 programs offering hands-on R&D exposure in high-growth therapeutic area
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 1
Clinical Trials (1)
NCT00351949IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
Phase 1Help build intelligence for Immutep
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.